Вагинальная сухость и качество жизни у женщин зрелого возраста

Обложка

Цитировать

Полный текст

Аннотация

Проблема сохранения качества жизни у стареющих женщин остается актуальной, особенно в свете принятой на государственном уровне концепции активного долголетия. Одним из важных компонентов качества жизни женщин в возрасте перименопаузы и постменопаузы является сексуальность, а существенным фактором снижения качества жизни становятся сексуальные расстройства. Нарушения сексуальной функции рассматриваются в рамках генитоуринарного синдрома (ГУМС), и в переходном периоде жизни женщины они чаще всего возникают в результате формирования вульвовагинальной атрофии. Следовательно, диагностика и терапия сексуальных расстройств у женщин в пери- и постменопаузе обычно лежат в плоскости диагностики и терапии ГУМС. В аналитическом обзоре рассматриваются вопросы эпидемиологии, диагностики и методов лечения симптомов вульвовагинальной атрофии с акцентом на сухость влагалища как наиболее частый и ранний признак заболевания, с одной стороны, и главная причина сексуальных нарушений у женщин менопаузального возраста - с другой. Предлагаются стандартные и вспомогательные методы терапии, которые при комплексном применении способны обеспечить улучшение качества сексуальной жизни с одновременной профилактикой прогрессирования ГУМС. Ключевые слова: менопауза, генитоуринарный менопаузальный синдром, вульвовагинальная атрофия, сухость влагалища, сексуальные нарушения, топические эстрогены, лубриканты, увлажняющие средства для вагинального применения. Для цитирования: Кузнецова И.В. Вагинальная сухость и качество жизни у женщин зрелого возраста. Consilium Medicum. 2020; 22 (6): 9-14. DOI: 10.26442/20751753.2020.6.200327

Об авторах

Ирина Всеволодовна Кузнецова

НОЧУ ДПО «Высшая медицинская школа»

Email: ms.smith.ivk@gmail.com
д-р мед. наук, проф., рук. направления Москва, Россия

Список литературы

  1. Palacios S, Henderson VW, Siseles N et al. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric 2010; 13: 419-28.
  2. Monteleone P, Mascagni G, Giannini A et al. Symptoms of menopause - global prevalence, physiology and implications. Nat Rev Endocrinol 2018; 14: 199-215.
  3. Davis SR, Lambrinoudaki I, Lumsden M et al. Menopause. Nat Rev Dis Primers. 2015; 1: 15004.
  4. Levine ME, Lu AT, Chen BH et al. Menopause accelerates biological aging. Proc Natl Acad Sci USA 2016;113:9327-32.
  5. Palacios S, Castelo-Branco C, Currie H et al. Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas 2015; 82: 308-13.
  6. Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019; 20: 821-35.
  7. Stika CS. Atrophic vaginitis. Dermatol Ther 2010; 23: 514-22.
  8. Brauer MM, Smith PG. Estrogen and female reproductive tract innervation: cellular and molecular mechanisms of autonomic neuro plasticity. Auton Neurosci 2015; 187: 1-17.
  9. Griebling TL, Liao Z, Smith PG. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause 2012; 19: 630-5.
  10. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause 2013; 20 (9): 888-902.
  11. Portman DJ, Gass MLS. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Maturitas 2014; 79(3): 349-54.
  12. Thurston RC. Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric 2018; 21: 96-100.
  13. Avis NE, Crawford SL, Green R. Vasomotor symptoms across the menopause transition: differences among women. Obstet Gynecol Clin North Am 2018; 45: 629-40.
  14. Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause 2018; 25: 1331-8.
  15. Nappi RE, Murina F, Perrone G et al. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol 2017; 69: 370-80.
  16. Mitchell CM, Waetjen LE. Genitourinary changes with aging. Obstet Gynecol Clin North Am 2018; 45: 737-50.
  17. Calleja-Aqius J, Brincat MP. The urogenital system and the menopause. Climacteric 2015; 18 (1): 18-22.
  18. Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J 2015; 26 (1): 15-28.
  19. Palacios S, Nappi RE, Bruyniks N et al; EVES Study Investigators. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric 2018; 21: 286-91.
  20. Parish SJ, Nappi RE, Krychman ML et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013; 5: 437-47.
  21. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric 2012; 15: 36-44.
  22. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010; 67: 233-8.
  23. Nappi RE, Palacios S, Particco M, Panay N. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: country-specific comparisons of postmenopausal women's perceptions, experiences and needs. Maturitas 2016; 91: 81-90.
  24. Krychman M, Graham S, Bernick B et al. The women's EMPOWER survey: women's knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med 2017;14:425-33.
  25. Faubion SS, Larkin LC, Stuenkel CA et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause 2018;25:596-608.
  26. Sadovsky R, Basson R, Krychman M et al. Cancer and sexual problems. J Sex Med 2010; 7: 349-73.
  27. Nappi RE, Cucinella L, Martini E et al. Sexuality in premature ovarian insufficiency. Climacteric 2019; 22: 289-95.
  28. Doumouchtsis SK, Chrysanthopoulou EL. Urogenital consequences in ageing women. Best Pract Res Clin Obstet Gynaecol 2013; 27: 699-714.
  29. Stiles M, Redmer J, Paddock E, Schrager S. Gynecologic issues in geriatric women. J Womens Health 2012; 21: 4-9.
  30. Thomas HN, Hess R, Thurston RC. Correlates of sexual activity and satisfaction in midlife and older women. Ann Fam Med 2015; 13: 336-42.
  31. Nappi RE, Albani F, Santamaria V et al. Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas 2010; 67: 78-83.
  32. Nappi RE, Seracchioli R, Salvatore S et al. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol 2019; 35: 453-9.
  33. Panay N, Palacios S, Bruyniks N et al; EVES Study Investigators. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas 2019; 124: 55-61.
  34. Nappi RE, Biglia N, Cagnacci A et al. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol Endocrinol 2016; 32: 602-6.
  35. Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med 2013; 10: 1567-74.
  36. Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc 2017; 92 (12): 1842-9.
  37. The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24 (7): 728-53.
  38. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016; 31: CD001500.
  39. American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014; 123 (1): 202-16.
  40. Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health 2018; 10: 387-95.
  41. Caruso S, Cianci S, Amore FF et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause 2016; 23 (1): 47-54.
  42. Mueck AO, Ruan X, Prasauskas V et al. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric 2018; 21 (2): 140-7.
  43. Kingsberg SA, Larkin L, Krychman M et al. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause 2019; 26 (2): 124-31.
  44. Bruyniks N, Nappi RE, Castelo-Branco C et al. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric 2016; 19: 60-5.
  45. Eden J. Managing menopausal symptoms after breast cancer. Eur J Endocrinol 2016; 174: R71-R77.
  46. Mazzarello S, Hutton B, Ibrahim MF et al. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat 2015;152:1-8.
  47. Hickey M, Marino J, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a sili-cone-versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat 2016; 158: 79-90.
  48. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016; 19: 151-61.
  49. Takacs P, Kozma B, Erdodi B et al. Zinc-containing Vaginal Moisturizer Gel Improves Postmenopausal Vulvovaginal Symptoms: A Pilot Study. J Menopausal Med 2019; 25 (1): 63-8. doi: 10.6118/jmm.2019.25.1.63
  50. Lee Y, Chung H, Kim J et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011; 117: 922-7.
  51. Carati D, Zizza A, Guido M et al. Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women. Clin Exp Obstet Gynecol 2016; 43 (2): 198-202.
  52. Stute P, May TW, Masur C et al. Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial. Climacteric 2015; 18 (4): 582-9. doi: 10.3109/13697137.2015.1036854
  53. Mitchell CM, Reed SD, Diem S et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA Intern Med 2018; 178 (5): 681-90. doi: 10.1001/jamainternmed.2018.0116
  54. Gibson CJ, Huang AJ, Larson JC et al. Patient-centered change in the day-to-day impact of postmenopausal vaginal symptoms: results from a multicenter randomized trial. Am J Obstet Gynecol 2020; 223 (1): 99.e1-99.e9. doi: 10.1016/j.ajog.2019.12.270
  55. Lukas VA, Simon JA. MsFLASH network vaginal health trial: absence of evidence is NOT evidence of absence. Menopause 2020; 27 (6): 722-5. doi: 10.1097/GME.0000000000001516

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2020

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).